Results 21 to 30 of about 642,659 (199)

Protective effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve of rats with diabetic peripheral neuropathy

Endocrine Journal
Dyslipidemia has been considered a risk factor for diabetic peripheral neuropathy. Proprotein convertase subtilisin-like/Kexin 9 inhibitor (PCSK9) inhibitors are a new type of lipid-lowering drug currently in clinical use.
Na Cui, Yonghao Feng, Ming Wang, Xiuyan Lu, Yongmei Huang, Yinghui Chen, Xiaohong Shi   +6 more
doaj   +2 more sources

Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors represent a promising class of lipid‐lowering therapy, although their use has been limited by cost concerns.
Elias J. Dayoub, Lauren A. Eberly, Ashwin S. Nathan, Sameed Ahmed M. Khatana, Srinath Adusumalli, Ann Marie Navar, Jay Giri, Peter W. Groeneveld   +7 more
doaj   +1 more source

PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer

Frontiers in Immunology, 2023
Proprotein convertase subtilisin/kexin type 9 (PCSK9) secreted by tumors was reported as a deleterious factor that led to the reduction of lymphocyte infiltration and the poorer efficacy of ICIs in vivo.
Xiang Gao, Xiang Gao, Ling Yi, Chang Jiang, Shuping Li, Xiaojue Wang, Bin Yang, Weiying Li, Nanying Che, Jinghui Wang, Jinghui Wang, Hongtao Zhang, Shucai Zhang   +12 more
doaj   +1 more source

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System

Cardiovascular Therapeutics, 2022
Background. Some studies suggest that potential safety issues about PCSK9 inhibitors have not been sufficiently explored in clinical trials, including musculoskeletal adverse events (MAEs). Objective.
Lingqing Ding, Congqin Chen, Yongkuan Yang, Jie Fang, Longxing Cao, Yige Liu   +5 more
doaj   +1 more source

The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia

Lipids in Health and Disease, 2021
Background As an autosomal dominant disorder, familial hypercholesterolemia (FH) is mainly attributed to disease-causing variants in the low-density lipoprotein receptor (LDLR) gene.
Haochang Hu, Ruoyu Chen, Yingchu Hu, Jian Wang, Shaoyi Lin, Xiaomin Chen   +5 more
doaj   +1 more source

Impact of early PCSK9 inhibitor treatment on heart after percutaneous coronary intervention in patients with STEMI: Design and rationale of the PERFECT II trial

Frontiers in Cardiovascular Medicine, 2022
Background and aimsPrimary percutaneous coronary intervention (PPCI) is the most effective treatment strategy for ST-segment elevation myocardial infarction (STEMI).
Jiachun Xia, Xinyue Wang, Jun Zhou, Dong Wang, Yanan Pang, Xin Xu, Zhenchi Sang, Yi Zhang, Junfeng Zhang, Sicheng Wu, Zhengguang Xiao, Lei Hou   +11 more
doaj   +1 more source

PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases [PDF]

Терапевтический архив, 2018
Aim. We study the dynamics of oxidatively modified low-density lipoprotein (ox-LDL) content in blood plasma, as well as changes in the activity of key antioxidant enzymes such as Se-containing glutathione peroxidase (GSH-Px) Cu,Zn-superoxide dismutase ...
V Z Lankin, A K Tikhaze, M Viigimaa, I E Chazova   +3 more
doaj   +1 more source

A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis [PDF]

Acta Pharmacologica Sinica
Sheng Ren, Yi-Ning Li, Shu-Yi Si
exaly   +2 more sources

Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review

Therapeutic Advances in Drug Safety, 2021
Neurocognitive adverse events have been observed with the widespread use of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors or “statins,” which reduce low-density lipoprotein cholesterol (LDL-C) levels and subsequently cardiovascular risk. The United
Wei C. Yuet, Didi Ebert, Michael Jann
doaj   +1 more source

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source